Pharmaceutical Executive November 17, 2022
Girisha Fernando

New regulations may require regulators to explore new payment options.

Few issues raise the ire of Americans more than the high cost of prescription drugs–and the Biden administration is seeking to tackle the issue through provisions in the recently passed Inflation Reduction Act. According to advocates, the law offers an effective way to begin the process of curbing high drug prices, thus making medical care more available and reducing costs to society. According to opponents, the new rules will harm innovation, with hundreds of potential treatments and cures left on the table because companies will have no financial incentive to pursue them.

That puts the government, the medical industry, and patients between a rock and a hard place: Cutting costs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Payment Models, Pharma, Pharma / Biotech, Value Based
GOP jumps on chance to bash Biden on Medicare
Does Medicare cover physical therapy? Yes, and you might be eligible for more services, too
CMMI’s Innovations in Behavioral Health: Promoting Physical and Mental Well-being
7 Tips for making the most of value-based care
Medicare Stumbles Managing a Costly Problem — Chronic Illness

Share This Article